Form 4: Apyx Medical Corp Director Michael Geraghty Acquires 17,000 Stock Options

Director Michael Geraghty acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.

Summary

• Michael Geraghty, a director of Apyx Medical Corp, acquired 17,000 stock options on August 8, 2024.
• The options have an exercise price of $1.02.
• These options were issued as part of the Issuer's Director Compensation Program.
• The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the grant date.
• The options expire on August 8, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction related to director compensation, which is generally viewed as a positive aspect of corporate governance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard disclosure related to director compensation, common in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages often include stock options to align the interests of directors with those of shareholders.
• The vesting schedule of 12 months is a common practice in the industry.
• The specific number of options granted and the exercise price would need to be compared to similar companies in the medical device industry to assess its competitiveness.

Related Party Transactions

• The issuance of stock options to Michael Geraghty, a director, is a related party transaction.

Stakeholder Impact

• The issuance of stock options to a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates